STX-001

Strand Therapeutics announced preliminary Phase 1 data for STX-001, a self-replicating mRNA therapy encoding IL-12, showing favorable safety and encouraging anti-tumor activity in 22 patients with checkpoint inhibitor-refractory solid tumors.

Strand Therapeutics' STX-003 demonstrates first-in-class ability to target IL-12 expression specifically to tumor tissues when delivered systemically, potentially overcoming toxicity challenges that have limited cytokine therapies.

Strand Therapeutics has dosed the first patient with STX-001, marking the entry of the first programmable mRNA therapy in oncology into clinical trials for solid tumors.